Inovio Pharmaceuticals confirms financial runway through Q1 2027 as its lead drug candidate nears October 2026 regulatory decision.
Inovio Pharmaceuticals announced its cash runway will extend into Q1 2027, providing financial stability as it advances INO-3107 toward a regulatory milestone. The company’s lead candidate targets an October 30, 2026 PDUFA date, a key step in its development pipeline.
Management highlighted progress during its Q1 2026 earnings call, emphasizing focus on INO-3107’s regulatory process. The drug’s PDUFA date marks a critical near-term catalyst for the biotech firm, which has prioritized pipeline execution.
No immediate market reaction was disclosed in the update. Inovio’s financial runway extension removes near-term liquidity concerns as it awaits the regulatory outcome.